Novo Nordisk AS
NVO
Company Profile
Business description
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Contact
Novo Alle 1
Bagsvaerd2880
DNKT: +45 44448888
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
78,554
Novo Nordisk AS News & Analysis
stocks
2 companies poised to capitalize on the rise of GLP-1 drugs
Why Pfizer and Roche look like top choices for investors in the war to tip the scales.
markets
December 2025 US stock market outlook: Where we see investment opportunities
Heading into year-end, Santa Claus Rally or AI exhaustion?
stocks
3 ‘buy the dip’ candidates with wide moats
Does recent share price weakness spell opportunity in these three high-quality companies?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,033.00 | 3.90 | -0.04% |
| CAC 40 | 8,195.21 | 45.71 | 0.56% |
| DAX 40 | 24,539.34 | 48.93 | 0.20% |
| Dow JONES (US) | 48,382.39 | 319.10 | 0.66% |
| FTSE 100 | 9,951.14 | 19.76 | 0.20% |
| HKSE | 26,314.64 | 23.83 | -0.09% |
| NASDAQ | 23,235.63 | 6.36 | -0.03% |
| Nikkei 225 | 51,628.66 | 1,289.18 | 2.56% |
| NZX 50 Index | 13,573.84 | 25.42 | 0.19% |
| S&P 500 | 6,858.47 | 12.97 | 0.19% |
| S&P/ASX 200 | 8,727.20 | 1.20 | 0.01% |
| SSE Composite Index | 4,011.45 | 42.61 | 1.07% |